EFMC-ACSMEDI Medicinal Chemistry Frontiers 2024

Joint Symposium on Medicinal Chemistry

 Utrecht, The Netherlands    April 8-11, 2024

Plenary lectures

The Polarities of Drug Discovery (PL02)

Dr Hayley BINCH
Dr Hayley BINCH
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Cancer Drug Discovery Using Fragment-Based Methods (PL03)

Prof. Stephen W. FESIK
Prof. Stephen W. FESIK
VANDERBILT UNIVERSITY, Nashville, United States
Read more

Medicinal Chemistry: Some Possible Future Directions (PL01)

Dr Mark MURCKO
Dr Mark MURCKO
DEWPOINT THERAPEUTICS, Boston, MA, United States
Read more

Invited Lectures

Antibody Discovery vs Challenging Proteins (IL11)

Dr Francesco APRILE
Dr Francesco APRILE
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

Unlocking the 14-3-3 Interactome for Drug Discovery (IL05)

Prof. Luc BRUNSVELD
Prof. Luc BRUNSVELD
EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands
Read more

Discovery of a Potent and Brain Penetrant O-GlcNAcase (OGA) Inhibitor Able to Reduce Tau Pathology in a Preclinical Animal Model (IL17)

Dr Peter BUIJNSTERS
Dr Peter BUIJNSTERS
JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium
Read more

Catalent’s SMARTag® Technology: Novel Linker Solutions Enable Improved Tolerability of Solid Tumor-Targeting ADCs (IL08)

Dr Stepan CHUPRAKOV
Dr Stepan CHUPRAKOV
CATALENT PHARMA SOLUTIONS INC, Emeryville, United States
Read more

Recent Advances in DNA-encoded Library Technology at GSK (IL01)

Dr Melissa GRENIER-DAVIES
Dr Melissa GRENIER-DAVIES
GLAXOSMITHKLINE, Cambridge, MA, United States
Read more

From Protein Structures to Bioactive Proteomimetics (IL06)

Prof. Tom GROSSMANN
Prof. Tom GROSSMANN
VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands
Read more

Development of Orally Bioavailable Peptides Targeting an Intra-cellular Protein: From a Hit to a Clinical KRAS Inhibitor (IL09)

Dr Ryuji HAYASHI
Dr Ryuji HAYASHI
CHUGAI PHARMACEUTICAL CO.,LTD., Kanagawa , Japan
Read more

Discovery of Quemliclustat, a Potent and Selective Small Molecule Inhibitor of CD73 (IL15)

Dr Jenna L. JEFFREY
Dr Jenna L. JEFFREY
ARCUS BIOSCIENCES, Hayward, CA, United States
Read more

Targeted Protein Degradation Using Cereblon Molecular Glues (IL10)

Dr Lyn H. JONES
Dr Lyn H. JONES
DANA FARBER CANCER INSTITUTE, Boston, MA, United States
Read more

Discovery of a Highly Specific, Potent, and Orally Efficacious LMP7 (β5i) Inhibitor (IL16)

Dr Markus KLEIN
Dr Markus KLEIN
MERCK KGAA, Darmstadt, Germany

In silico enabled discovery of KAI-11101, a DLK inhibitor for the treatment of neurodegenerative diseases (IL18)

Dr H. Rachel LAGIAKOS
Dr H. Rachel LAGIAKOS
SCHRÖDINGER, New York, NY, United States
Read more

Hybrid Compounds for Neurodegenerative Diseases: from Small Molecules to Targeted Therapies ( (IL19)

Prof. Maria Joao MATOS
Prof. Maria Joao MATOS
UNIVERSITY OF SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain
Read more

From Molecules to Molecular Surfaces and Back Again. Exploiting the Synergy between Electrochemistry and Organic Synthesis (IL13)

Prof. Kevin MOELLER
Prof. Kevin MOELLER
WASHINGTON UNIVERSITY, Saint Louis, MO, United States
Read more

Dynamics and Mechanism of CRISPR-Cas9 through the Lens of Computational Methods (IL12)

Dr Giulia PALERMO
Dr Giulia PALERMO
UNIVERSITY OF CALIFORNIA RIVERSIDE, Riverside, United States
Read more

Click Chemistry in the Discovery of a Modulator of the Store-Operated Calcium Entry for the Treatment for Rare Genetic Myopathies (IL14)

Prof. Tracey PIRALI
Prof. Tracey PIRALI
UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy
Read more

Targeted Cancer Therapy with Best-in-Class Antibody-Drug Conjugates Based on Clinical-Stage GlycoConnect™ and HydraSpace Technologies (IL07)

Dr Floris VAN DELFT
Dr Floris VAN DELFT
SYNAFFIX, Oss, The Netherlands
Read more

Site Directed Hit Discovery Using Biophysical Assays (IL04)

Dr Johan VEERMAN
Dr Johan VEERMAN
ZOBIO BV, Leiden, The Netherlands
Read more

Fragment-Based Drug Design of Allosteric SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2) Inhibitors (IL03)

Dr Alison WOOLFORD
Dr Alison WOOLFORD
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

Development of SAR-CoV-2 Mpro Inhibitors Using DNA-Encoded Chemical Libraries (IL02)

Prof. Damian YOUNG
Prof. Damian YOUNG
BAYLOR COLLEGE OF MEDICINE, Houston, TX, United States
Read more

Oral Communications

Peptides from Bench to Clinical Studies: Our Experience with CXCR4 (OC09)

Dr Salvatore DI MARO
Dr Salvatore DI MARO
UNIVERSITÀ DEGLI STUDI DELLA CAMPANIA, CASERTA, Italy
Read more

Leveraging New Chemical Modalities for Reprogramming IDO1 Half-Life in Cancer Immunotherapy (OC18)

Dr Rita Maria Concetta DI MARTINO
Dr Rita Maria Concetta DI MARTINO
UNIVERSITÀ DEL PIEMONTE ORIENTALE , Novara , Italy
Read more

Targeted Protein Degradation of GPCRS: A Case Study of Novel CCR2 PROTACs (OC08)

Mr Khaled ESSA
Mr Khaled ESSA
LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

Selective Substrate Identification Using Chemically Modified Phage Display (OC12)

Mr Franco FAUCHER
Mr Franco FAUCHER
STANFORD UNIVERSITY, Stanford, United States
Read more

Discovery of Hedgehog Acyltransferase (HHAT) Inhibitors as a Novel Strategy to Stop Hedgehog Signalling in Cancer (OC11)

Dr Efthymios S. GAVRIIL
Dr Efthymios S. GAVRIIL
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

Fighting Chronic Neuroinflammation with Novel P2X7 Receptor Antagonists: An Intriguing Therapeutic Approach to the Neurodegenerative Diseases (OC20)

Dr Imane GHAFIR EL IDRISSI
Dr Imane GHAFIR EL IDRISSI
UNIVERSITY OF BARI ALDO MORO, Bari, Italy
Read more

Development and Crystallographic Screening of a Fully Sociable and Diverse Fragment Library (OC03)

Mr Philipp JANSSEN
Mr Philipp JANSSEN
UNIVERSITY OF MÜNSTER, Muenster, Germany
Read more

A Hybrid of mRNA Display and DNA-Encoded Libraries for Discovery of Extended Rule of 5 Molecules (OC01)

Dr Seino JONGKEES
Dr Seino JONGKEES
VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands
Read more

Development of New SARS-CoV-2 NSP13 Inhibitors as a Promising Strategy to Block Viral Replication (OC06)

Dr Valentina Noemi MADIA
Dr Valentina Noemi MADIA
SAPIENZA, UNIVERSITY OF ROME, Roma, Italy
Read more

Late-Stage Functionalization in Drug Discovery: from Academic Collaborations to Applications in Medicinal Chemistry (OC16)

Dr Antonio MISALE
Dr Antonio MISALE
JANSSEN R&D, Toledo, Spain
Read more

Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2)(OC07)

Dr Natalia V. ORTIZ ZACARIAS
Dr Natalia V. ORTIZ ZACARIAS
LACDR, LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

Preclinical Development of Innovative TLR4 Modulators as Vaccine Adjuvants and Immunotherapeutics (OC17)

Prof. Francesco PERI
Prof. Francesco PERI
UNIVERSITY OF MILANO/BICOCCA, Milano, Italy
Read more

DELs in Cells - Direct Screening for Molecular Glue (OC02)

Dr Rico Gerup PETERSEN
Dr Rico Gerup PETERSEN
VIPERGEN, Copenhagen, Denmark
Read more

Innovative Synthetic Methods to Accelerate Drug Discovery (OC15)

Dr Stefan SCHIESSER
Dr Stefan SCHIESSER
ASTRAZENECA, Mölndal, Sweden
Read more

Potent Bispecific T Cell Engagers Obtained by Tyrosine Click Chemistry (OC13)

Ms Irene SHAJAN
Ms Irene SHAJAN
WAGENINGEN UNIVERSITY & RESEARCH, Wageningen, The Netherlands
Read more

Fragment-Based Drug Discovery of Photopharmacological Agents (OC04)

Mr Kim Tai TRAN
Mr Kim Tai TRAN
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

Discovery of a Brain Penetrant Covalent BTK Inhibitor with a Novel Asn-484 Interaction (OC19)

Mr George VANDEVEER
Mr George VANDEVEER
BIOGEN, Stoneham, United States
Read more

Native Mass Spectrometry as a Tool for Rapid Elucidation and Modulation of Transient Protein-Protein Interactions (OC05)

Prof. Clinton VEALE
Prof. Clinton VEALE
UNIVERSITY OF CAPE TOWN, Cape Town, South Africa
Read more